Cargando…
Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?
The pandemic of the new coronavirus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has urged the nations to an unprecedented world-wide reaction, including an accelerated exploration of therapeutic options. In the absence of a vaccine and specifically designed antivirals, th...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267470/ https://www.ncbi.nlm.nih.gov/pubmed/32495226 http://dx.doi.org/10.1007/s10067-020-05202-4 |
_version_ | 1783541445553029120 |
---|---|
author | Ibáñez, Sebastián Martínez, Oriela Valenzuela, Francisca Silva, Francisco Valenzuela, Omar |
author_facet | Ibáñez, Sebastián Martínez, Oriela Valenzuela, Francisca Silva, Francisco Valenzuela, Omar |
author_sort | Ibáñez, Sebastián |
collection | PubMed |
description | The pandemic of the new coronavirus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has urged the nations to an unprecedented world-wide reaction, including an accelerated exploration of therapeutic options. In the absence of a vaccine and specifically designed antivirals, the medical community has proposed the use of various previously available medications in order to reduce the number of patients requiring prolonged hospitalizations, oxygen therapy, and mechanical ventilation and to decrease mortality from coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine are among the proposed drugs and are the most widely used so far, despite the lack of robust evidence on their usefulness. The objective of this article is to review and discuss the possible role of these drugs in the therapy of COVID-19. |
format | Online Article Text |
id | pubmed-7267470 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-72674702020-06-03 Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy? Ibáñez, Sebastián Martínez, Oriela Valenzuela, Francisca Silva, Francisco Valenzuela, Omar Clin Rheumatol Perspectives in Rheumatology The pandemic of the new coronavirus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has urged the nations to an unprecedented world-wide reaction, including an accelerated exploration of therapeutic options. In the absence of a vaccine and specifically designed antivirals, the medical community has proposed the use of various previously available medications in order to reduce the number of patients requiring prolonged hospitalizations, oxygen therapy, and mechanical ventilation and to decrease mortality from coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine are among the proposed drugs and are the most widely used so far, despite the lack of robust evidence on their usefulness. The objective of this article is to review and discuss the possible role of these drugs in the therapy of COVID-19. Springer International Publishing 2020-06-03 2020 /pmc/articles/PMC7267470/ /pubmed/32495226 http://dx.doi.org/10.1007/s10067-020-05202-4 Text en © International League of Associations for Rheumatology (ILAR) 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Perspectives in Rheumatology Ibáñez, Sebastián Martínez, Oriela Valenzuela, Francisca Silva, Francisco Valenzuela, Omar Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy? |
title | Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy? |
title_full | Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy? |
title_fullStr | Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy? |
title_full_unstemmed | Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy? |
title_short | Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy? |
title_sort | hydroxychloroquine and chloroquine in covid-19: should they be used as standard therapy? |
topic | Perspectives in Rheumatology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267470/ https://www.ncbi.nlm.nih.gov/pubmed/32495226 http://dx.doi.org/10.1007/s10067-020-05202-4 |
work_keys_str_mv | AT ibanezsebastian hydroxychloroquineandchloroquineincovid19shouldtheybeusedasstandardtherapy AT martinezoriela hydroxychloroquineandchloroquineincovid19shouldtheybeusedasstandardtherapy AT valenzuelafrancisca hydroxychloroquineandchloroquineincovid19shouldtheybeusedasstandardtherapy AT silvafrancisco hydroxychloroquineandchloroquineincovid19shouldtheybeusedasstandardtherapy AT valenzuelaomar hydroxychloroquineandchloroquineincovid19shouldtheybeusedasstandardtherapy |